MSLN and acute myeloid leukemia: Preclinical studies to evaluate the efficacy of mesothelin-targeted therapies such as immunotoxin, ADC, BiTEs, CAR-T cells, and CAR-NK cells in pediatric AML have been conducted (Figure 3).